Abbott Laboratories is writing one of the biggest checks in diagnostic medicine history — and it’s betting that check will reshape how cancer gets caught, and how early.
The Chicago-based healthcare giant has agreed to acquire Exact Sciences for roughly $21 billion in an all-cash deal, paying $105 per share for the Madison, Wisconsin-based company best known for its Cologuard colorectal cancer screening test. The total enterprise value, including approximately $1.8 billion in net debt, comes to around $23 billion. Abbott expects to close the transaction in the second quarter of 2026 — with a specific target date of March 23, 2026 — pending final regulatory sign-offs, which are already well along their way.
A Strategic Swing, Not a Defensive Play
This isn’t the kind of acquisition a company makes to protect turf. It’s the kind it makes when it thinks it sees something the market hasn’t fully priced in yet. “We’re making a pretty significant move here that is more long term in terms of how we see medical need and clinical need across the global healthcare markets,” Abbott chairman and CEO Robert B. Ford told reporters. That’s the kind of language executives use when they’re not just buying revenue — they’re buying a thesis.
And the revenue is already there. Exact Sciences is projected to generate more than $3 billion this year alone, with high-teens organic sales growth that most diagnostics companies would kill for. Once the deal closes, Abbott’s combined diagnostics business is expected to exceed $12 billion in annual sales, cementing its position as one of the most formidable diagnostics platforms on the planet. That’s not a small footnote — that’s a category-defining moment for the company and, arguably, for the broader cancer screening industry.
Shareholders Weren’t Hard to Convince
Here’s one number that tells you everything about how Exact Sciences investors felt about this deal: more than 99% of votes cast were in favor of the acquisition, representing 67% of the company’s outstanding shares. That’s not a close call. That’s a standing ovation. The shareholder vote, approved in February 2026, effectively removed one of the last major hurdles standing between Abbott and the finish line.
Regulatory clearances have followed in kind. The mandatory Hart-Scott-Rodino antitrust waiting period has already expired, as noted by financial analysts tracking the deal’s progress. That expiration is a significant procedural milestone — it means the Department of Justice and Federal Trade Commission have passed on raising any formal objections, at least within the standard review window.
Financing a $21 Billion Bet
Still, writing a $21 billion check requires more than confidence. Abbott went to the debt markets to fund the purchase, completing a $20 billion bond offering — one of the larger corporate debt issuances in recent memory. The offering was executed ahead of the expected close, signaling that Abbott’s treasury team wasn’t leaving the financing to chance. It’s a bold move that adds leverage to the balance sheet, though Abbott has consistently argued that Exact Sciences’ growth trajectory more than justifies the cost of capital.
Ford has framed the acquisition in explicitly long-range terms, which is notable given the near-term pressure most public company CEOs face from Wall Street. “Proactively shaping the portfolio to anticipate future medical needs while building long-term shareholder value remains at the core of our strategic framework,” he said in the initial announcement. That’s a sentence designed to reassure investors who might be nervous about a deal of this size — but it also reflects a genuine strategic logic that’s hard to argue with.
Why Exact Sciences? Why Now?
Cancer screening is having a moment. The science of catching tumors earlier — through blood-based liquid biopsies, stool DNA tests, and precision oncology tools — has accelerated dramatically over the past decade. Exact Sciences sits squarely at the intersection of those trends. Its flagship Cologuard product has become a household name in colorectal screening, and the company has been expanding aggressively into broader oncology diagnostics. For Abbott, acquiring Exact Sciences isn’t just about adding a product line. It’s about acquiring a platform, a brand, and a patient base in one of the fastest-growing segments of global healthcare, as outlined in the companies’ joint announcement.
That said, it’s not that simple. Integrating a company of this size — with its own culture, its own sales infrastructure, and its own clinical pipeline — is the part of M&A that rarely gets the headlines but almost always determines whether a deal ultimately succeeds. Abbott has done this before, and at scale. But the diagnostics landscape is changing fast, and the margin for misstep is thinner than it looks from the outside.
The full terms of the deal, including the per-share price and enterprise value breakdown, were disclosed in a formal press release at the time of the announcement. If all goes according to plan, the transaction will officially close in the coming weeks — and Abbott will wake up on the other side of it as a fundamentally different company than it was before.
Whether that difference turns out to be a masterstroke or an overreach, history tends to answer those questions slowly — and usually not in the quarter the deal closes.
